Clinical Trials - LXRX

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06481891A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyRECRUITINGPHASE32024-09-242026-082026-07
NCT06203002A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)COMPLETEDPHASE22023-11-292025-02-242025-01-14
NCT04662281Efficacy and Safety of LX9211 in Participants With Postherpetic NeuralgiaCOMPLETEDPHASE22020-12-292022-12-212022-11-18
NCT04455633Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainCOMPLETEDPHASE22020-09-032022-06-282022-05-23
NCT03521934Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)TERMINATEDPHASE32018-06-152020-06-052020-06-05
NCT03386344Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlTERMINATEDPHASE32018-02-192020-05-302019-05-22
NCT03315143Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskTERMINATEDPHASE32017-12-192020-07-082020-07-08
NCT03292653Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart FailureTERMINATEDPHASE22017-12-042019-08-172019-08-17
NCT03332771Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyCOMPLETEDPHASE32017-12-012019-09-062019-08-06
NCT03423446Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic ImpairmentCOMPLETEDPHASE12017-11-282018-06-152018-06-15
NCT03351478Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminCOMPLETEDPHASE32017-11-272019-05-162019-05-16
NCT03302845A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy SubjectsCOMPLETEDPHASE12017-09-212017-11-072017-10-23
NCT03285594Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsCOMPLETEDPHASE32017-09-152019-09-272019-09-17
NCT03242018A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlCOMPLETEDPHASE32017-08-162019-12-112019-05-16
NCT03242252Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlCOMPLETEDPHASE32017-08-162019-10-252019-03-25
NCT03066830Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With MetforminCOMPLETEDPHASE32017-02-242019-04-302019-04-17
NCT02926937Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic TherapyCOMPLETEDPHASE32016-11-112019-05-172019-04-22
NCT02926950Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminCOMPLETEDPHASE32016-112019-03-222019-02-26
NCT02647918Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal FunctionCOMPLETEDPHASE12015-122017-092017-09
NCT02531035A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneCOMPLETEDPHASE32015-092017-042017-04
NCT02459899Dose-ranging Study in Patients With Type 1 Diabetes MellitusCOMPLETEDPHASE22015-072016-082016-08
NCT02494609Oral Contraceptive DDI StudyUNKNOWNPHASE12015-072015-11
NCT02471274PK Study of Sotagliflozin in Subjects With Hepatic ImpairmentCOMPLETEDPHASE12015-062015-12
NCT02421510Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCOMPLETEDPHASE32015-052017-06-232016-11
NCT02383940Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1CCOMPLETEDPHASE22015-042016-092016-09
NCT02384941Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCOMPLETEDPHASE32015-032017-022016-09
NCT02373046Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 TabletsCOMPLETEDPHASE12015-022015-04
NCT02300363DDI Study With Multiple-dose LX4211 and Single Dose RosuvastatinCOMPLETEDPHASE12014-102014-112014-11
NCT02300350DDI Study With Multiple-dose LX4211 and Single Dose DigoxinCOMPLETEDPHASE12014-102014-122014-12
NCT02195635Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy SubjectsCOMPLETEDPHASE12014-072014-10
NCT02157558An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy SubjectsCOMPLETEDPHASE12014-072014-08
NCT02157584An Open-Label Food Effect Study of Telotristat EtiprateCOMPLETEDPHASE12014-062014-07
NCT02155205A Thorough QT Study of Telotristat EtiprateCOMPLETEDPHASE12014-052014-08
NCT02147808A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy SubjectsCOMPLETEDPHASE12014-052014-08
NCT02063659Telotristat Etiprate for Carcinoid Syndrome TherapyCOMPLETEDPHASE32014-03-112016-03-292016-03-29
NCT02026063Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsCOMPLETEDPHASE32014-01-142018-09-122018-09-12
NCT01916850Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy SubjectsCOMPLETEDPHASE12013-082013-10
NCT01916863Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult SubjectsCOMPLETEDPHASE12013-082013-10
NCT01932528An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in MalesCOMPLETEDPHASE12013-082013-09
NCT01913002Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy SubjectsCOMPLETEDPHASE12013-072013-10
NCT01818232Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male SubjectsCOMPLETEDPHASE12013-032013-052013-05
NCT01742208Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusCOMPLETEDPHASE22013-022014-012014-01
NCT01677910TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)COMPLETEDPHASE32013-01-082016-03-212016-03-21
NCT01528111Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCOMPLETEDPHASE1, PHASE22012-032012-062012-06
NCT01555008Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal ImpairmentCOMPLETEDPHASE12012-032013-08
NCT01494233A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel SyndromeCOMPLETEDPHASE22012-022013-09
NCT01456052A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative ColitisCOMPLETEDPHASE22012-01-302013-09-032013-09-03
NCT01441232A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsCOMPLETEDPHASE12011-102011-11
NCT01417052A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid ArthritisCOMPLETEDPHASE12011-092012-062012-06
NCT01411800An Open-Label Study of Two Formulations of LX1033 in Healthy Human SubjectsCOMPLETEDPHASE12011-082012-052011-10
NCT01376557Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on MetforminCOMPLETEDPHASE22011-062012-052012-05
NCT01334242A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy SubjectsCOMPLETEDPHASE12011-032011-04
NCT01292993A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy SubjectsCOMPLETEDPHASE12011-022011-03
NCT01188863Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes MellitusCOMPLETEDPHASE12010-092010-10
NCT01104415Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid SyndromeCOMPLETEDPHASE22010-06-152014-02-122014-02-12
NCT00962065Study of LX4211 in Subjects With Type 2 Diabetes MellitusCOMPLETEDPHASE22009-082009-12
NCT00903383Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable MethotrexateCOMPLETEDPHASE22009-072010-09
NCT00853047Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCOMPLETEDPHASE22009-032014-062014-06
NCT00847886Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid ArthritisCOMPLETEDPHASE12009-022009-032009-03
NCT00813098Study of LX1031 in Subjects With Non-Constipating Irritable Bowel SyndromeCOMPLETEDPHASE22008-122010-082009-07
NCT00691808Study of LX6171 in Elderly Volunteers With Age Associated Memory ImpairmentCOMPLETEDPHASE22008-022008-10